<DOC>
	<DOCNO>NCT02162550</DOCNO>
	<brief_summary>Investigators determine whether weekly injectable medication Bydureon versus placebo able reduce development atherosclerosis . Investigators test overall hypothesis 18 month Bydureon treatment improve cardiovascular risk factor , endothelial function retard carotid atherosclerosis plaque progression type 2 diabetes mellitus ( T2DM ) . Investigators anticipate study provide novel information temporal relationship Bydureon induce change risk factor , endothelial function atherosclerosis progression .</brief_summary>
	<brief_title>Effect Bydureon Carotid Atherosclerosis Progression Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>148 typical T2DM patient ( age 21-75 ) participate roll recruitment approximately 2.25 year randomly allocate 18 month Bydureon ( 2 mg/week ) match placebo subcutaneous injection 1x/week 2:1 ratio . Participants expect wide range cardiovascular ( CVD ) risk therefore allow u explore importance disease extent baseline predictor response . Blocked randomization use ensure equal distribution gender CVD history . Carotid plaque MRI assessment perform baseline , 9 18 month .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>male female race ethnicity T2DM , HbA1c ≥6.5 % ≤10.0 % diet take stable dos oral antihyperglycemic agent without longacting insulin must regular primary care provider ( PCP ) amenable patient study participation facilitate ( blind treatment ) research team 's study protocol effort type 1 diabetes mellitus ( T1DM ) current recent glucagonlike peptide 1 receptor ( GLP1R ) agonist use contraindication MRI ( e.g. , claustrophobia , ferromagnetic material , body habitus inappropriate MRI exam ) screen carotid ultrasound plaque thickness &lt; 0.75 mm , prior anticipate carotid stenting endarterectomy recent CVD ( past 6 month ) major illness condition affect risk ( e.g. , pancreatitis , severe renal disease ) personal family history medullary thyroid carcinoma patient Multiple Endocrine Neoplasia syndrome type 2 serious hypersensitivity exenatide product component severe gastrointestinal disease , pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Carotid Plaque</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Incretins</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>